BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Clinical Trials (1)
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Started Jul 2022
60 enrolled
Lymphoma, Large B-Cell, Diffuse (DLBCL)